BRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology

Reuters

Feb 09

BRIEF-Memo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology

Feb 9 (Reuters) - CSL Ltd CSL.AX:

MEMO THERAPEUTICS AG ENTERS INTO A COLLABORATION AND OPTION AGREEMENT WITH CSL FOR DEVELOPMENT OF RECOMBINANT POLYCLONAL IGG TECHNOLOGY
MEMO THERAPEUTICS AG: AGREEMENT INCLUDES RESEARCH AND DEVELOPMENT FUNDING FOR EXPLORATORY WORK, TECHNOLOGY ACCESS
MEMO THERAPEUTICS AG: CO WILL DEVELOP RECOMBINANT POLYCLONAL IGG USING DROPZYLLA PLATFORM TO CLONE ANTIBODY REPERTOIRES,EXPRESS ANTIBODIES

Source text: ID:nGNXbydlsF

Further company coverage: CSL.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610637722"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610637722\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610637722?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610637722","market":"us","top_or_hot":-1,"title":"BRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Memo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology</title></head><body><p><span>Feb 9 (Reuters)</span><span> - </span>CSL Ltd <span>CSL.AX</span>:</p><ul><li><p>MEMO THERAPEUTICS AG ENTERS INTO A COLLABORATION AND OPTION AGREEMENT WITH CSL FOR DEVELOPMENT OF RECOMBINANT POLYCLONAL <a href=\"https://laohu8.com/S/00799\">IGG</a> TECHNOLOGY</p></li><li><p>MEMO THERAPEUTICS AG: AGREEMENT INCLUDES RESEARCH AND DEVELOPMENT FUNDING FOR EXPLORATORY WORK, TECHNOLOGY ACCESS</p></li><li><p>MEMO THERAPEUTICS AG: CO WILL DEVELOP RECOMBINANT POLYCLONAL IGG USING DROPZYLLA PLATFORM TO CLONE ANTIBODY REPERTOIRES,EXPRESS ANTIBODIES</p></li></ul><p>Source text: <span>ID:nGNXbydlsF</span></p><p>Further company coverage: <span>CSL.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-09 20:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Memo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg Technology</title></head><body><p><span>Feb 9 (Reuters)</span><span> - </span>CSL Ltd <span>CSL.AX</span>:</p><ul><li><p>MEMO THERAPEUTICS AG ENTERS INTO A COLLABORATION AND OPTION AGREEMENT WITH CSL FOR DEVELOPMENT OF RECOMBINANT POLYCLONAL <a href=\"https://laohu8.com/S/00799\">IGG</a> TECHNOLOGY</p></li><li><p>MEMO THERAPEUTICS AG: AGREEMENT INCLUDES RESEARCH AND DEVELOPMENT FUNDING FOR EXPLORATORY WORK, TECHNOLOGY ACCESS</p></li><li><p>MEMO THERAPEUTICS AG: CO WILL DEVELOP RECOMBINANT POLYCLONAL IGG USING DROPZYLLA PLATFORM TO CLONE ANTIBODY REPERTOIRES,EXPRESS ANTIBODIES</p></li></ul><p>Source text: <span>ID:nGNXbydlsF</span></p><p>Further company coverage: <span>CSL.AX</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z515R:1","article_id":"2610637722","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610637722","pubTimestamp":1770639539,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg TechnologyFeb 9 (Reuters) - CSL Ltd CSL.AX:MEMO THERAPEUTICS AG ENTER","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","CSL.AU":"CSL LIMITED","BK7067":"生物科技","BK7508":"医药生物股","BK7511":"ESG概念"},"translate_title":"BRIEF-Memo Therapeutics AG与Csl签订合作和期权协议，开发重组多克隆Igg技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9},"content_text":"BRIEF-Memo Therapeutics AG Enters Into A Collaboration And Option Agreement With Csl For Development Of Recombinant Polyclonal Igg TechnologyFeb 9 (Reuters) - CSL Ltd CSL.AX:MEMO THERAPEUTICS AG ENTERS INTO A COLLABORATION AND OPTION AGREEMENT WITH CSL FOR DEVELOPMENT OF RECOMBINANT POLYCLONAL IGG TECHNOLOGYMEMO THERAPEUTICS AG: AGREEMENT INCLUDES RESEARCH AND DEVELOPMENT FUNDING FOR EXPLORATORY WORK, TECHNOLOGY ACCESSMEMO THERAPEUTICS AG: CO WILL DEVELOP RECOMBINANT POLYCLONAL IGG USING DROPZYLLA PLATFORM TO CLONE ANTIBODY REPERTOIRES,EXPRESS ANTIBODIESSource text: ID:nGNXbydlsFFurther company coverage: CSL.AX ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}